Enzo Biochem Inc. (NYSE:ENZ) shares were down 4.6% during mid-day trading on Monday . The company traded as low as $5.16 and last traded at $5.19, with a volume of 133,430 shares trading hands. The stock had previously closed at $5.44.

Separately, Zacks Investment Research raised shares of Enzo Biochem from a “sell” rating to a “hold” rating in a research note on Tuesday, May 24th.

The stock’s 50-day moving average price is $5.92 and its 200 day moving average price is $5.62. The stock has a market cap of $238.26 million, a price-to-earnings ratio of 13.48 and a beta of 1.50.

A number of large investors have recently made changes to their positions in the stock. California State Teachers Retirement System purchased a new stake in shares of Enzo Biochem during the second quarter valued at $497,000. Bank of New York Mellon Corp boosted its stake in shares of Enzo Biochem by 89.8% in the second quarter. Bank of New York Mellon Corp now owns 187,262 shares of the company’s stock valued at $1,119,000 after buying an additional 88,602 shares during the last quarter. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Enzo Biochem by 102.0% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 852,438 shares of the company’s stock valued at $5,089,000 after buying an additional 430,395 shares during the last quarter. ClariVest Asset Management LLC boosted its stake in shares of Enzo Biochem by 4.4% in the second quarter. ClariVest Asset Management LLC now owns 265,503 shares of the company’s stock valued at $1,585,000 after buying an additional 11,300 shares during the last quarter. Finally, Strs Ohio purchased a new stake in shares of Enzo Biochem during the second quarter valued at $653,000. 53.29% of the stock is owned by institutional investors and hedge funds.

Enzo Biochem Company Profile

Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.

5 Day Chart for NYSE:ENZ

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.